# US 2005/0233449 A1 · Simple and rapid derivation of functional hepatocytes from human bone marrow-derived mesenchymal stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0233449 A1
- Document ID: US20050233449A1
- Status: Published application
- Kind: A1
- Application number: 11/099,451
- Filed: 2005-04-06
- Published: 2005-10-20
- Earliest claimed: 2004-04-16
- Inventors: Kuan-Der Lee; Jacqueline Whang-Peng
- Web page: https://patentgrep.com/patent/US20050233449A1

## CPC

- C12N 5/067: {Hepatocytes}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 2500/38: Vitamins
- C12N 2501/06: Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/33: Insulin
- C12N 2501/39: Steroid hormones
- C12N 2503/00: Use of cells in diagnostics
- C12N 2503/04: Screening or testing on artificial tissues
- C12N 2506/1353: from bone marrow mesenchymal stem cells (BM-MSC)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This disclosure provides methods for preparing hepatocytes from mesenchymal stem cells by culturing in a first culture media comprising hepatocyte growth factor and a second culture media comprising oncostatin-M. The disclosure also provides the MSC-derived hepatocytes produced by these methods and both in vivo and in vitro uses for these MSC-derived hepatocytes.

## Claims

### Claim 1

A method for inducing differentiation of mesenchymal stem cells into hepatocytes in vitro comprising incubating cultured mesenchymal stem cells with a first culture media comprising hepatocyte growth factor followed by incubating the cells with a second culture media comprising oncostatin-M.

### Claim 2 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells comprise cells isolated from the iliac crest of a patient donor.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mesenchymal stems cells are subjected to immunodepletion of cells expressing CD3, CD14, CD19, CD38, CD66b, and/or glycophorin A before culturing.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mesenchymal stem cells are of human origin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first culture media further comprises fibroblast growth factor, nicotinamide, or both.

### Claim 6 (depends on 1)

The method of claim 1, wherein the second culture media further comprises dexamethasone, insulin, or both.

### Claim 7

A composition comprising mesenchymal stem cell (MSC)-derived hepatocytes.

### Claim 8 (depends on 1, 7)

The composition of claim 7, wherein the MSC-derived hepatocytes are produced by the method of claim 1.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the mesenchymal stem cells are isolated from the iliac crest of a patient donor.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the mesenchymal stems cells are subjected to immunodepletion of cells expressing CD3, CD14, CD19, CD38, CD66b, and/or glycophorin A before culturing.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the mesenchymal stem cells are of human origin.

### Claim 12 (depends on 7)

The composition of claim 7, wherein the first culture media further comprises fibroblast growth factor, nicotinamide, or both.

### Claim 13 (depends on 7)

The composition of claim 7, wherein the second culture media further comprises dexamethasone, insulin, or both.

### Claim 14

A method for repairing liver damage in a patient, comprising administering MSC-derived hepatocytes.

### Claim 15 (depends on 1, 14)

The method of claim 14, wherein the MSC-derived hepatocytes are produced by the method of claim 1.

### Claim 16

A method for growing liver tissue in vitro comprising repeated culturing and expansion of MSC-derived hepatocytes.

### Claim 17 (depends on 16)

The method of claim 16, wherein the culturing and expansion occurs in a culture media comprising hepatocyte growth factor, oncostatin-M, or both.

### Claim 18 (depends on 16)

A composition comprising liver tissue produced by the method of claim 16.

### Claim 19 (depends on 7, 18)

A method for the in vitro growth of liver-specific viruses comprising incubating the virus with a composition of claim 7 or 18.

### Claim 20 (depends on 7, 18)

A method of screening a compound for its effect on hepatocytes or hepatocyte activity, comprising:
a) combining the compound with a composition of claim 7 or 18;
b) determining any change to MSC-derived hepatocytes or their activity as a result of contact with the compound; and
c) correlating the change with the effect of the compound on hepatocytes or hepatocyte activity.

### Claim 21 (depends on 20)

The method of claim 20, further comprising determining whether the compound is toxic to MSC-derived hepatocytes.

### Claim 22 (depends on 20)

The method of claim 20, further comprising determining whether the compound affects ability of MSC-derived hepatocytes to proliferate or be maintained in culture.

### Claim 23 (depends on 20)

The method of claim 20, further comprising determining whether the compound changes enzyme activity or secretion normally present in MSC-derived hepatocytes.

### Claim 24 (depends on 20)

The method of claim 20, wherein the MSC-derived hepatocytes have been genetically altered.

### Claim 25

A kit for the preparation of MSC-derived hepatocytes comprising a first culture media comprising hepatocyte growth factor, and a second culture media comprising oncostatin-M.

### Claim 26 (depends on 25)

The kit of claim 25, wherein the first culture media further comprises FGF, nicotinamide, or both.

### Claim 27 (depends on 25)

The kit of claim 25, wherein the second culture media further comprises dexamethasone, insulin, or both.

### Claim 28 (depends on 25)

The kit of claim 25 further comprising cultured mesenchymal stem cells.

### Claim 29

A kit for the in vitro growth of liver-specific viruses comprising MSC-derived hepatocytes.
